article thumbnail

Gluten in Medications: Why Labeling Matters for Patients With Celiac Disease

Drug Topics

Despite pleas from celiac disease advocates, the FDA still does not require drug manufacturers to note on the label whether a medication contains gluten.

Labelling 504
article thumbnail

FDA Approves Updated Label for Altuviiio for Effective Bleed Protection in Children Younger than 12 Years

Drug Topics

Altuviiio was first granted approval by the FDA in February 2023.

Labelling 504
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Updated Buprenorphine Label For Rapid Initiation Treatment

Drug Topics

The updated label also includes alternative injection sites, such as the abdomen, thigh, buttock, or back of the upper arm.

Labelling 217
article thumbnail

Lantidra Cell Therapy for Type 1 Diabetes Approved by FDA

Drug Topics

The approval was based on safety and efficacy data from 30 participants in 2 open-label, single-arm studies that received 1 to 3 infusions of donislecel.

Labelling 469
article thumbnail

FDA Roundup: Updated Label for Altuviiio, CRL Given to Heplisav-B

Drug Topics

Check out important updates from the FDA for the week of May 13.

Labelling 247
article thumbnail

FDA Requires Abrysvo, Arexvy RSV Vaccine Labels to Include Guillain-Barré Warning

Drug Topics

Patients who receive either Pfizer or GSKs respiratory syncytial virus vaccine may be at increased risk of Guillain-Barr syndrome.

Vaccines 309
article thumbnail

FDA issues warnings to GLP-1 compounders

The Checkup by Singlecare

Food and Drug Administration (FDA) is sounding the alarm about the risks of using unapproved GLP-1s. Earlier this month, the FDA posted four warning letters to companies that have introduced unapproved GLP-1s, such as semaglutide, tirzepatide, and retatrutide, into interstate commerce. But the U.S. Which companies are affected?